FDA Poised To Backtrack On Peptide Ban After RFK Jr. Push

Federal regulators are moving toward restoring legal access to a slate of injectable peptides that were effectively barred from pharmacy compounding in 2023, a shift that, if finalized, could pull patients away from sketchy online sellers and back under the care of licensed pharmacies and prescribing clinicians. According to The New York Times, senior administration officials say the Food and Drug Administration is expected to lift restrictions on a group of injectable peptides after a review prompted by Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy told the Joe Rogan Experience that he had used some of the products "to heal injuries, with really good effect," and has said roughly 14 previously restricted compounds could be made more accessible.

Background: The 2023 Restrictions

In late 2023 the FDA moved more than a dozen widely used research peptides onto a Category 2 list, saying those substances raised significant safety concerns and were not eligible for routine compounding. The agency's guidance explains that Category 2 designations reflect potential risks, including impurities, immunogenicity and insufficient human data, that prompted enforcement priorities against routine compounding, according to the FDA.

Expert Concerns and Industry Reaction

Public health experts warn that reversing course could normalize unproven injectables and weaken the drug approval process. A commentary in BioCentury argued the move "would legitimize unproven injectables while weakening century-old drug safeguards," even as some clinicians and compounding advocates counter that returning these peptides to regulated pharmacy channels would reduce harm from tainted products sold online.

What This Would Mean For Patients

If the FDA changes the bulks list as signaled, licensed 503A pharmacies could legally compound certain peptides for individual patients with prescriptions, but that status would not equate to FDA approval or robust clinical proof of safety and effectiveness, according to PolitiFact. The issue has also played out in industry meetings and public comments as supplement makers and compounding groups press regulators to expand access, according to reporting by the Associated Press.

What To Watch Next

Any durable change will require formal agency action and, in many cases, publication in the Federal Register. Until then, patients who want peptide therapies are being urged to consult a licensed clinician and be wary of online vendors selling "research-use" vials. Regulators and industry watchers say the coming weeks should clarify which compounds, if any, move back into routine compounding and how the supply chain for those products will be monitored.